nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Methotrexate—bone cancer	0.346	0.462	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—bone cancer	0.201	0.269	CbGbCtD
Valsartan—ALB—Methotrexate—bone cancer	0.11	0.147	CbGbCtD
Valsartan—CYP2C9—Cisplatin—bone cancer	0.0915	0.122	CbGbCtD
Valsartan—Irbesartan—JUN—bone cancer	0.0119	0.652	CrCbGaD
Valsartan—Tasosartan—CYP3A4—bone cancer	0.00305	0.167	CrCbGaD
Valsartan—Irbesartan—CYP3A4—bone cancer	0.002	0.11	CrCbGaD
Valsartan—Losartan—CYP3A4—bone cancer	0.00129	0.0708	CrCbGaD
Valsartan—Renal failure acute—Methotrexate—bone cancer	0.00116	0.00497	CcSEcCtD
Valsartan—Flatulence—Cisplatin—bone cancer	0.00115	0.00496	CcSEcCtD
Valsartan—Photosensitivity—Epirubicin—bone cancer	0.00114	0.00489	CcSEcCtD
Valsartan—Muscle spasms—Cisplatin—bone cancer	0.00113	0.00484	CcSEcCtD
Valsartan—Vision blurred—Cisplatin—bone cancer	0.0011	0.00474	CcSEcCtD
Valsartan—Renal failure acute—Epirubicin—bone cancer	0.00108	0.00465	CcSEcCtD
Valsartan—Photosensitivity—Doxorubicin—bone cancer	0.00105	0.00452	CcSEcCtD
Valsartan—Renal impairment—Epirubicin—bone cancer	0.00105	0.00451	CcSEcCtD
Valsartan—Dermatitis bullous—Epirubicin—bone cancer	0.00105	0.00449	CcSEcCtD
Valsartan—Cardiac failure—Epirubicin—bone cancer	0.00102	0.0044	CcSEcCtD
Valsartan—Hyponatraemia—Epirubicin—bone cancer	0.001	0.00431	CcSEcCtD
Valsartan—Renal failure acute—Doxorubicin—bone cancer	0.001	0.0043	CcSEcCtD
Valsartan—Myalgia—Cisplatin—bone cancer	0.000998	0.00429	CcSEcCtD
Valsartan—Anxiety—Cisplatin—bone cancer	0.000994	0.00427	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000991	0.00426	CcSEcCtD
Valsartan—Renal impairment—Doxorubicin—bone cancer	0.000972	0.00417	CcSEcCtD
Valsartan—Dermatitis bullous—Doxorubicin—bone cancer	0.000968	0.00416	CcSEcCtD
Valsartan—Oedema—Cisplatin—bone cancer	0.000957	0.00411	CcSEcCtD
Valsartan—Anaphylactic shock—Cisplatin—bone cancer	0.000957	0.00411	CcSEcCtD
Valsartan—Infection—Cisplatin—bone cancer	0.00095	0.00408	CcSEcCtD
Valsartan—Cardiac failure—Doxorubicin—bone cancer	0.000948	0.00407	CcSEcCtD
Valsartan—Nervous system disorder—Cisplatin—bone cancer	0.000938	0.00403	CcSEcCtD
Valsartan—Thrombocytopenia—Cisplatin—bone cancer	0.000937	0.00402	CcSEcCtD
Valsartan—Blood creatinine increased—Epirubicin—bone cancer	0.000936	0.00402	CcSEcCtD
Valsartan—Skin disorder—Cisplatin—bone cancer	0.000929	0.00399	CcSEcCtD
Valsartan—Hyponatraemia—Doxorubicin—bone cancer	0.000928	0.00399	CcSEcCtD
Valsartan—Orthostatic hypotension—Epirubicin—bone cancer	0.000913	0.00392	CcSEcCtD
Valsartan—Abdominal pain upper—Epirubicin—bone cancer	0.000913	0.00392	CcSEcCtD
Valsartan—Anorexia—Cisplatin—bone cancer	0.000912	0.00392	CcSEcCtD
Valsartan—Hypotension—Cisplatin—bone cancer	0.000894	0.00384	CcSEcCtD
Valsartan—Muscular weakness—Epirubicin—bone cancer	0.000881	0.00379	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000871	0.00374	CcSEcCtD
Valsartan—Blood creatinine increased—Doxorubicin—bone cancer	0.000866	0.00372	CcSEcCtD
Valsartan—Neutropenia—Methotrexate—bone cancer	0.000863	0.00371	CcSEcCtD
Valsartan—Paraesthesia—Cisplatin—bone cancer	0.000859	0.00369	CcSEcCtD
Valsartan—Upper respiratory tract infection—Methotrexate—bone cancer	0.000858	0.00368	CcSEcCtD
Valsartan—Dyspnoea—Cisplatin—bone cancer	0.000853	0.00366	CcSEcCtD
Valsartan—Erectile dysfunction—Methotrexate—bone cancer	0.00085	0.00365	CcSEcCtD
Valsartan—Abdominal pain upper—Doxorubicin—bone cancer	0.000845	0.00363	CcSEcCtD
Valsartan—Orthostatic hypotension—Doxorubicin—bone cancer	0.000845	0.00363	CcSEcCtD
Valsartan—Photosensitivity reaction—Methotrexate—bone cancer	0.000843	0.00362	CcSEcCtD
Valsartan—Decreased appetite—Cisplatin—bone cancer	0.000832	0.00357	CcSEcCtD
Valsartan—Bronchitis—Epirubicin—bone cancer	0.000831	0.00357	CcSEcCtD
Valsartan—Gastrointestinal disorder—Cisplatin—bone cancer	0.000826	0.00355	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—bone cancer	0.000823	0.00353	CcSEcCtD
Valsartan—Infestation—Methotrexate—bone cancer	0.000823	0.00353	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—bone cancer	0.000816	0.0035	CcSEcCtD
Valsartan—Renal failure—Methotrexate—bone cancer	0.000809	0.00347	CcSEcCtD
Valsartan—Neutropenia—Epirubicin—bone cancer	0.000808	0.00347	CcSEcCtD
Valsartan—Upper respiratory tract infection—Epirubicin—bone cancer	0.000803	0.00345	CcSEcCtD
Valsartan—Photosensitivity reaction—Epirubicin—bone cancer	0.000788	0.00339	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—bone cancer	0.000776	0.00333	CcSEcCtD
Valsartan—Infestation NOS—Epirubicin—bone cancer	0.00077	0.00331	CcSEcCtD
Valsartan—Infestation—Epirubicin—bone cancer	0.00077	0.00331	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—bone cancer	0.000769	0.0033	CcSEcCtD
Valsartan—Renal failure—Epirubicin—bone cancer	0.000757	0.00325	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—bone cancer	0.000747	0.00321	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000743	0.00319	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—bone cancer	0.000743	0.00319	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—bone cancer	0.000739	0.00317	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—bone cancer	0.000739	0.00317	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—bone cancer	0.000733	0.00315	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—bone cancer	0.00073	0.00313	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—bone cancer	0.00073	0.00313	CcSEcCtD
Valsartan—Epistaxis—Epirubicin—bone cancer	0.000726	0.00312	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—bone cancer	0.000724	0.00311	CcSEcCtD
Valsartan—Sinusitis—Epirubicin—bone cancer	0.000723	0.0031	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—bone cancer	0.000713	0.00306	CcSEcCtD
Valsartan—Infestation—Doxorubicin—bone cancer	0.000713	0.00306	CcSEcCtD
Valsartan—Hypersensitivity—Cisplatin—bone cancer	0.000705	0.00303	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—bone cancer	0.000701	0.00301	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—bone cancer	0.000695	0.00298	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—bone cancer	0.000693	0.00298	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—bone cancer	0.000691	0.00297	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—bone cancer	0.000691	0.00297	CcSEcCtD
Valsartan—Asthenia—Cisplatin—bone cancer	0.000686	0.00295	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—bone cancer	0.000686	0.00295	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—bone cancer	0.000686	0.00294	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—bone cancer	0.000683	0.00293	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—bone cancer	0.000679	0.00292	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—bone cancer	0.000678	0.00291	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—bone cancer	0.000672	0.00289	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—bone cancer	0.00067	0.00288	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—bone cancer	0.000669	0.00287	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—bone cancer	0.000667	0.00287	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—bone cancer	0.000666	0.00286	CcSEcCtD
Valsartan—Diarrhoea—Cisplatin—bone cancer	0.000654	0.00281	CcSEcCtD
Valsartan—Alopecia—Methotrexate—bone cancer	0.000653	0.0028	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—bone cancer	0.000647	0.00278	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—bone cancer	0.000643	0.00276	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—bone cancer	0.000643	0.00276	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—bone cancer	0.000642	0.00276	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—bone cancer	0.000641	0.00275	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—bone cancer	0.00064	0.00275	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—bone cancer	0.00064	0.00275	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—bone cancer	0.000635	0.00273	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—bone cancer	0.000632	0.00271	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—bone cancer	0.00063	0.0027	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—bone cancer	0.000629	0.0027	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—bone cancer	0.000627	0.00269	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—bone cancer	0.000627	0.00269	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—bone cancer	0.000625	0.00268	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—bone cancer	0.000623	0.00268	CcSEcCtD
Valsartan—Back pain—Methotrexate—bone cancer	0.000622	0.00267	CcSEcCtD
Valsartan—Alopecia—Epirubicin—bone cancer	0.000611	0.00262	CcSEcCtD
Valsartan—Vomiting—Cisplatin—bone cancer	0.000608	0.00261	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—bone cancer	0.000606	0.0026	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—bone cancer	0.000606	0.0026	CcSEcCtD
Valsartan—Rash—Cisplatin—bone cancer	0.000603	0.00259	CcSEcCtD
Valsartan—Dermatitis—Cisplatin—bone cancer	0.000603	0.00259	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—bone cancer	0.000602	0.00258	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—bone cancer	0.000594	0.00255	CcSEcCtD
Valsartan—Flatulence—Epirubicin—bone cancer	0.000593	0.00255	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—bone cancer	0.000589	0.00253	CcSEcCtD
Valsartan—Back pain—Epirubicin—bone cancer	0.000582	0.0025	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—bone cancer	0.00058	0.00249	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—bone cancer	0.000579	0.00249	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—bone cancer	0.000578	0.00248	CcSEcCtD
Valsartan—Vertigo—Methotrexate—bone cancer	0.000578	0.00248	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—bone cancer	0.000577	0.00248	CcSEcCtD
Valsartan—Nausea—Cisplatin—bone cancer	0.000568	0.00244	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—bone cancer	0.000567	0.00244	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—bone cancer	0.000565	0.00243	CcSEcCtD
Valsartan—Cough—Methotrexate—bone cancer	0.000561	0.00241	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—bone cancer	0.00056	0.00241	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—bone cancer	0.000557	0.00239	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—bone cancer	0.000549	0.00236	CcSEcCtD
Valsartan—Chest pain—Methotrexate—bone cancer	0.000548	0.00235	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—bone cancer	0.000548	0.00235	CcSEcCtD
Valsartan—Myalgia—Methotrexate—bone cancer	0.000548	0.00235	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—bone cancer	0.000545	0.00234	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000544	0.00234	CcSEcCtD
Valsartan—Vertigo—Epirubicin—bone cancer	0.000541	0.00232	CcSEcCtD
Valsartan—Syncope—Epirubicin—bone cancer	0.00054	0.00232	CcSEcCtD
Valsartan—Back pain—Doxorubicin—bone cancer	0.000539	0.00231	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—bone cancer	0.000535	0.0023	CcSEcCtD
Valsartan—Palpitations—Epirubicin—bone cancer	0.000532	0.00228	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—bone cancer	0.000529	0.00227	CcSEcCtD
Valsartan—Cough—Epirubicin—bone cancer	0.000525	0.00226	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—bone cancer	0.000525	0.00225	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—bone cancer	0.000525	0.00225	CcSEcCtD
Valsartan—Infection—Methotrexate—bone cancer	0.000521	0.00224	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—bone cancer	0.000515	0.00221	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—bone cancer	0.000514	0.00221	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—bone cancer	0.000512	0.0022	CcSEcCtD
Valsartan—Chest pain—Epirubicin—bone cancer	0.000512	0.0022	CcSEcCtD
Valsartan—Myalgia—Epirubicin—bone cancer	0.000512	0.0022	CcSEcCtD
Valsartan—Anxiety—Epirubicin—bone cancer	0.000511	0.00219	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—bone cancer	0.00051	0.00219	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000509	0.00219	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—bone cancer	0.000501	0.00215	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—bone cancer	0.0005	0.00215	CcSEcCtD
Valsartan—Anorexia—Methotrexate—bone cancer	0.0005	0.00215	CcSEcCtD
Valsartan—Syncope—Doxorubicin—bone cancer	0.000499	0.00214	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—bone cancer	0.000492	0.00211	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—bone cancer	0.000491	0.00211	CcSEcCtD
Valsartan—Oedema—Epirubicin—bone cancer	0.000491	0.00211	CcSEcCtD
Valsartan—Hypotension—Methotrexate—bone cancer	0.00049	0.00211	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—bone cancer	0.000489	0.0021	CcSEcCtD
Valsartan—Infection—Epirubicin—bone cancer	0.000488	0.0021	CcSEcCtD
Valsartan—Cough—Doxorubicin—bone cancer	0.000486	0.00209	CcSEcCtD
Valsartan—Shock—Epirubicin—bone cancer	0.000483	0.00208	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—bone cancer	0.000482	0.00207	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—bone cancer	0.000481	0.00207	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000478	0.00205	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—bone cancer	0.000477	0.00205	CcSEcCtD
Valsartan—Insomnia—Methotrexate—bone cancer	0.000475	0.00204	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—bone cancer	0.000474	0.00204	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—bone cancer	0.000474	0.00204	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—bone cancer	0.000474	0.00204	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—bone cancer	0.000472	0.00203	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—bone cancer	0.000471	0.00202	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000471	0.00202	CcSEcCtD
Valsartan—Anorexia—Epirubicin—bone cancer	0.000468	0.00201	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—bone cancer	0.000468	0.00201	CcSEcCtD
Valsartan—Somnolence—Methotrexate—bone cancer	0.000467	0.002	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—bone cancer	0.000464	0.00199	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—bone cancer	0.000462	0.00198	CcSEcCtD
Valsartan—Hypotension—Epirubicin—bone cancer	0.000459	0.00197	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—bone cancer	0.000456	0.00196	CcSEcCtD
Valsartan—Oedema—Doxorubicin—bone cancer	0.000455	0.00195	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—bone cancer	0.000455	0.00195	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—bone cancer	0.000453	0.00195	CcSEcCtD
Valsartan—Fatigue—Methotrexate—bone cancer	0.000453	0.00194	CcSEcCtD
Valsartan—Infection—Doxorubicin—bone cancer	0.000452	0.00194	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000448	0.00192	CcSEcCtD
Valsartan—Shock—Doxorubicin—bone cancer	0.000447	0.00192	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—bone cancer	0.000446	0.00191	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—bone cancer	0.000445	0.00191	CcSEcCtD
Valsartan—Insomnia—Epirubicin—bone cancer	0.000444	0.00191	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—bone cancer	0.000441	0.0019	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—bone cancer	0.000441	0.00189	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—bone cancer	0.000438	0.00188	CcSEcCtD
Valsartan—Somnolence—Epirubicin—bone cancer	0.000437	0.00188	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—bone cancer	0.000433	0.00186	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—bone cancer	0.000432	0.00186	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—bone cancer	0.000429	0.00184	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—bone cancer	0.000427	0.00183	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—bone cancer	0.000425	0.00182	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—bone cancer	0.000424	0.00182	CcSEcCtD
Valsartan—Fatigue—Epirubicin—bone cancer	0.000424	0.00182	CcSEcCtD
Valsartan—Constipation—Epirubicin—bone cancer	0.00042	0.0018	CcSEcCtD
Valsartan—Urticaria—Methotrexate—bone cancer	0.000417	0.00179	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—bone cancer	0.000415	0.00178	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000414	0.00178	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—bone cancer	0.000411	0.00177	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—bone cancer	0.000408	0.00175	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—bone cancer	0.000405	0.00174	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—bone cancer	0.000404	0.00174	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—bone cancer	0.000402	0.00173	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—bone cancer	0.0004	0.00172	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—bone cancer	0.000395	0.0017	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000392	0.00169	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—bone cancer	0.000392	0.00168	CcSEcCtD
Valsartan—Urticaria—Epirubicin—bone cancer	0.00039	0.00168	CcSEcCtD
Valsartan—Constipation—Doxorubicin—bone cancer	0.000389	0.00167	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—bone cancer	0.000388	0.00167	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—bone cancer	0.000387	0.00166	CcSEcCtD
Valsartan—Asthenia—Methotrexate—bone cancer	0.000377	0.00162	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—bone cancer	0.000372	0.0016	CcSEcCtD
Valsartan—Pruritus—Methotrexate—bone cancer	0.000371	0.00159	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—bone cancer	0.000362	0.00155	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—bone cancer	0.000361	0.00155	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—bone cancer	0.000359	0.00154	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—bone cancer	0.000359	0.00154	CcSEcCtD
Valsartan—Asthenia—Epirubicin—bone cancer	0.000352	0.00151	CcSEcCtD
Valsartan—Pruritus—Epirubicin—bone cancer	0.000348	0.00149	CcSEcCtD
Valsartan—Dizziness—Methotrexate—bone cancer	0.000347	0.00149	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—bone cancer	0.000336	0.00144	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—bone cancer	0.000335	0.00144	CcSEcCtD
Valsartan—Vomiting—Methotrexate—bone cancer	0.000334	0.00143	CcSEcCtD
Valsartan—Rash—Methotrexate—bone cancer	0.000331	0.00142	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—bone cancer	0.000331	0.00142	CcSEcCtD
Valsartan—Headache—Methotrexate—bone cancer	0.000329	0.00141	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—bone cancer	0.000326	0.0014	CcSEcCtD
Valsartan—Dizziness—Epirubicin—bone cancer	0.000325	0.0014	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—bone cancer	0.000322	0.00138	CcSEcCtD
Valsartan—Vomiting—Epirubicin—bone cancer	0.000312	0.00134	CcSEcCtD
Valsartan—Nausea—Methotrexate—bone cancer	0.000312	0.00134	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—bone cancer	0.000311	0.00134	CcSEcCtD
Valsartan—Rash—Epirubicin—bone cancer	0.00031	0.00133	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—bone cancer	0.000309	0.00133	CcSEcCtD
Valsartan—Headache—Epirubicin—bone cancer	0.000308	0.00132	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—bone cancer	0.000301	0.00129	CcSEcCtD
Valsartan—Nausea—Epirubicin—bone cancer	0.000292	0.00125	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—bone cancer	0.000289	0.00124	CcSEcCtD
Valsartan—Rash—Doxorubicin—bone cancer	0.000287	0.00123	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—bone cancer	0.000286	0.00123	CcSEcCtD
Valsartan—Headache—Doxorubicin—bone cancer	0.000285	0.00122	CcSEcCtD
Valsartan—Nausea—Doxorubicin—bone cancer	0.00027	0.00116	CcSEcCtD
Valsartan—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	1.3e-05	0.0883	CbGpPWpGaD
Valsartan—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	1.22e-05	0.0827	CbGpPWpGaD
Valsartan—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	8.34e-06	0.0564	CbGpPWpGaD
Valsartan—AGTR1—Arf6 signaling events—GNA11—bone cancer	7.54e-06	0.051	CbGpPWpGaD
Valsartan—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	7.14e-06	0.0483	CbGpPWpGaD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	6.08e-06	0.0411	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—FOLR1—bone cancer	5.93e-06	0.0401	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	5.81e-06	0.0393	CbGpPWpGaD
Valsartan—AGTR1—Arf6 signaling events—MET—bone cancer	4.24e-06	0.0287	CbGpPWpGaD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	3.28e-06	0.0222	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—GRM1—bone cancer	3.06e-06	0.0207	CbGpPWpGaD
Valsartan—CYP2C9—Xenobiotics—CYP3A4—bone cancer	2.93e-06	0.0198	CbGpPWpGaD
Valsartan—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	2.82e-06	0.0191	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	2.74e-06	0.0185	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—bone cancer	2.66e-06	0.018	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	2.61e-06	0.0177	CbGpPWpGaD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	2.43e-06	0.0165	CbGpPWpGaD
Valsartan—AGTR1—Arf6 signaling events—EGFR—bone cancer	2.15e-06	0.0145	CbGpPWpGaD
Valsartan—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	2.01e-06	0.0136	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—GNA11—bone cancer	1.97e-06	0.0133	CbGpPWpGaD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	1.92e-06	0.013	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—GRM4—bone cancer	1.78e-06	0.012	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	1.76e-06	0.0119	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—DHFR—bone cancer	1.63e-06	0.011	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—GRM1—bone cancer	1.54e-06	0.0104	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—SPARC—bone cancer	1.42e-06	0.00964	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	1.36e-06	0.00919	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.28e-06	0.00866	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	1.22e-06	0.00824	CbGpPWpGaD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	1.2e-06	0.00813	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.1e-06	0.00747	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—SMO—bone cancer	1.09e-06	0.00736	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GRM4—bone cancer	1.01e-06	0.00681	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—RGS1—bone cancer	1.01e-06	0.00681	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NDUFA12—bone cancer	1e-06	0.00677	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.87e-07	0.00668	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GRM4—bone cancer	9.14e-07	0.00618	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RGS1—bone cancer	9.14e-07	0.00618	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GRM1—bone cancer	8.72e-07	0.0059	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.59e-07	0.00582	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NT5C3A—bone cancer	8.29e-07	0.00561	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GRM1—bone cancer	7.92e-07	0.00536	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.42e-07	0.00502	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NDUFA12—bone cancer	6.72e-07	0.00455	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	6.32e-07	0.00428	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	6.24e-07	0.00422	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	5.78e-07	0.00391	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GNA11—bone cancer	5.62e-07	0.0038	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—SMO—bone cancer	5.58e-07	0.00378	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NT5C3A—bone cancer	5.57e-07	0.00377	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GRM4—bone cancer	5.4e-07	0.00365	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RGS1—bone cancer	5.4e-07	0.00365	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.24e-07	0.00355	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	5.24e-07	0.00355	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.17e-07	0.0035	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GNA11—bone cancer	5.11e-07	0.00345	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL3—bone cancer	5.1e-07	0.00345	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	5.02e-07	0.0034	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.91e-07	0.00332	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	4.85e-07	0.00328	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GRM1—bone cancer	4.68e-07	0.00317	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL3—bone cancer	4.63e-07	0.00313	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.48e-07	0.00303	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.42e-07	0.00299	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.24e-07	0.00287	CbGpPWpGaD
Valsartan—ALB—Metabolism—NDUFA12—bone cancer	3.84e-07	0.0026	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—bone cancer	3.63e-07	0.00246	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ENO2—bone cancer	3.63e-07	0.00246	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—DHFR—bone cancer	3.37e-07	0.00228	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SMO—bone cancer	3.3e-07	0.00223	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SPARC—bone cancer	3.26e-07	0.0022	CbGpPWpGaD
Valsartan—ALB—Metabolism—NT5C3A—bone cancer	3.18e-07	0.00215	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GNA11—bone cancer	3.15e-07	0.00213	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NDUFA12—bone cancer	3.14e-07	0.00213	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GNA11—bone cancer	3.02e-07	0.00204	CbGpPWpGaD
Valsartan—ALB—Hemostasis—GNA11—bone cancer	2.98e-07	0.00202	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP3A4—bone cancer	2.85e-07	0.00193	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.84e-07	0.00192	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ATF1—bone cancer	2.8e-07	0.0019	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL3—bone cancer	2.73e-07	0.00185	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL3—bone cancer	2.7e-07	0.00183	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NT5C3A—bone cancer	2.6e-07	0.00176	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTP1—bone cancer	2.44e-07	0.00165	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ENO2—bone cancer	2.44e-07	0.00165	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFBR2—bone cancer	2.34e-07	0.00158	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—DHFR—bone cancer	2.26e-07	0.00153	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1R—bone cancer	2.2e-07	0.00149	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNA11—bone cancer	2.11e-07	0.00143	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP3A4—bone cancer	1.92e-07	0.0013	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.91e-07	0.00129	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAU—bone cancer	1.77e-07	0.0012	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—bone cancer	1.64e-07	0.00111	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIT—bone cancer	1.6e-07	0.00108	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—bone cancer	1.5e-07	0.00101	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—bone cancer	1.45e-07	0.000984	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO2—bone cancer	1.39e-07	0.000943	CbGpPWpGaD
Valsartan—ALB—Metabolism—DHFR—bone cancer	1.29e-07	0.000875	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—bone cancer	1.26e-07	0.000855	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—bone cancer	1.26e-07	0.00085	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNA11—bone cancer	1.21e-07	0.000817	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO2—bone cancer	1.14e-07	0.000772	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP3A4—bone cancer	1.1e-07	0.000741	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—bone cancer	1.09e-07	0.000739	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.09e-07	0.000737	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—bone cancer	1.06e-07	0.000719	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—DHFR—bone cancer	1.06e-07	0.000716	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNA11—bone cancer	9.89e-08	0.000669	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—bone cancer	9.37e-08	0.000634	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP3A4—bone cancer	8.97e-08	0.000607	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.92e-08	0.000604	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—bone cancer	8.59e-08	0.000581	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—bone cancer	8.49e-08	0.000575	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—bone cancer	7.67e-08	0.000519	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—bone cancer	7.21e-08	0.000488	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—bone cancer	7.12e-08	0.000482	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—bone cancer	4.85e-08	0.000328	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—bone cancer	3.97e-08	0.000269	CbGpPWpGaD
